| Product Code: ETC9949823 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Next Generation Immunology Drugs Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Next Generation Immunology Drugs Market - Industry Life Cycle |
3.4 United Kingdom (UK) Next Generation Immunology Drugs Market - Porter's Five Forces |
3.5 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume Share, By Therapeutic Area, 2021 & 2031F |
4 United Kingdom (UK) Next Generation Immunology Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of autoimmune diseases in the UK |
4.2.2 Growing awareness about the benefits of next-generation immunology drugs |
4.2.3 Technological advancements in drug development and personalized medicine |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval |
4.3.2 High cost associated with developing and manufacturing next-generation immunology drugs |
4.3.3 Competition from existing conventional therapies in the market |
5 United Kingdom (UK) Next Generation Immunology Drugs Market Trends |
6 United Kingdom (UK) Next Generation Immunology Drugs Market, By Types |
6.1 United Kingdom (UK) Next Generation Immunology Drugs Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Small Molecules, 2021- 2031F |
6.1.4 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Antibodies, 2021- 2031F |
6.1.5 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Cell Based Therapies, 2021- 2031F |
6.1.6 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Other Drug Classes, 2021- 2031F |
6.2 United Kingdom (UK) Next Generation Immunology Drugs Market, By Therapeutic Area |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Cancer, 2021- 2031F |
6.2.3 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Autoimmune Diseases, 2021- 2031F |
6.2.4 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.2.5 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Inflammatory Diseases, 2021- 2031F |
6.2.6 United Kingdom (UK) Next Generation Immunology Drugs Market Revenues & Volume, By Other Therapeutic Areas, 2021- 2031F |
7 United Kingdom (UK) Next Generation Immunology Drugs Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Next Generation Immunology Drugs Market Export to Major Countries |
7.2 United Kingdom (UK) Next Generation Immunology Drugs Market Imports from Major Countries |
8 United Kingdom (UK) Next Generation Immunology Drugs Market Key Performance Indicators |
8.1 Patient adherence rate to next-generation immunology drugs |
8.2 Number of clinical trials conducted for new immunology drugs in the UK |
8.3 Percentage of healthcare professionals recommending next-generation immunology drugs to patients |
9 United Kingdom (UK) Next Generation Immunology Drugs Market - Opportunity Assessment |
9.1 United Kingdom (UK) Next Generation Immunology Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 United Kingdom (UK) Next Generation Immunology Drugs Market Opportunity Assessment, By Therapeutic Area, 2021 & 2031F |
10 United Kingdom (UK) Next Generation Immunology Drugs Market - Competitive Landscape |
10.1 United Kingdom (UK) Next Generation Immunology Drugs Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Next Generation Immunology Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here